Sarepta Therapeutics, Inc. provided revenue guidance for the fourth quarter and full year 2022. For the quarter, net product revenues are expected to be approximately $235.5 million, a 32% increase over the same period in 2021. The expected net product revenues do not include collaboration revenues.
Net product revenues for the full-year 2022 are expected to be $843.3 million, a 38% increase over the same period of 2021, which is also expected to exceed SareptaÆs net product revenue guidance of $825 million to 840 million. The expected net product revenues do not include collaboration revenues.